Evaluation of Bleeding and Thrombotic Events during Long-Term Use of Romiplostim in Patients with Chronic Immune Thrombocytopenic Purpura.

Michael D. Tarantino(Bleeding & Clotting Disorders Institute), Terry Gernsheimer(Bloodworks Northwest), Louis M. Aledort(Icahn School of Medicine at Mount Sinai), Matthew Guo(Eisai (United States)), Dietmar Berger(Amgen (United States)), James N. George(University of Oklahoma), U. K. Sunkara(Alta Bates Summit Medical Center)
Blood
November 16, 2008
10.1182/blood.v112.11.3422.3422
Cited by 5

Related Papers

Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group
|Blood|2008|2.6k
Clinical Practice Guidelines From the AABB
|JAMA|2016|1.1k
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
|The Lancet|2008|862
Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis.
|PubMed|2001|803
Definitions in Hemophilia
|Thrombosis and Haemostasis|2001|772